Constraint-based perturbation analysis with cluster Newton method: a case study of personalized parameter estimations with irinotecan whole-body physiologically based pharmacokinetic model

被引:10
作者
Asami, Shun [1 ]
Kiga, Daisuke [1 ,2 ]
Konagaya, Akihiko [1 ,3 ,4 ]
机构
[1] Tokyo Inst Technol, Dept Computat Intelligence & Syst Sci, Midori Ku, 4259 Nagatsuda Cho, Yokohama, Kanagawa 2268503, Japan
[2] Waseda Univ, Dept Elect Engn & Biosci, Shinjuku Ku, 2-2 Wakamatsu Cho, Tokyo 1628480, Japan
[3] Tokyo Inst Technol, Sch Comp, Midori Ku, 4259 Nagatsuda Cho, Yokohama, Kanagawa 2268503, Japan
[4] Natl Inst Informat, Chiyoda Ku, 2-1-2 Hitotsubashi, Tokyo 1018430, Japan
关键词
Cluster Newton method; Constraint-based sensitivity analysis; PBPK models; Pharmacokinetics; Parameter estimation; CANCER-PATIENTS; METABOLISM; CPT-11; DRUGS; AGE;
D O I
10.1186/s12918-017-0513-2
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
Background: Drug development considering individual varieties among patients becomes crucial to improve clinical development success rates and save healthcare costs. As a useful tool to predict individual phenomena and correlations among drug characteristics and individual varieties, recently, whole-body physiologically based pharmacokinetic (WB-PBPK) models are getting more attention. WB-PBPK models generally have a lot of drug-related parameters that need to be estimated, and the estimations are difficult because the observed data are limited. Furthermore, parameter estimation in WB-PBPK models may cause overfitting when applying to individual clinical data such as urine/feces drug excretion for each patient in which Cluster Newton Method (CNM) is applicable for parameter estimation. In order to solve this issue, we came up with the idea of constraint-based perturbation analysis of the CNM. The effectiveness of our approach is demonstrated in the case of irinotecan WB-PBPK model using common organ-specific tissue-plasma partition coefficients (Kp) among the patients as constraints in WB-PBPK parameter estimation. Results: We find strong correlations between age, renal clearance and liver functions in irinotecan WB-PBPK model with personalized physiological parameters by observing the distributions of optimized values of strong convergence drug-related parameters using constraint-based perturbation analysis on CNM. The constraint-based perturbation analysis consists of the following three steps: (1) Estimation of all drug-related parameters for each patient; the parameters include organ-specific Kp. (2) Fixing suitable values of Kp for each organ among all patients identically. (3) Re-estimation of all drug-related parameters other than Kp by using the fixed values of Kp as constraints of CNM. Conclusions: Constraint-based perturbation analysis could yield new findings when using CNM with appropriate constraints. This method is a new technique to find suitable values and important insights that are masked by CNM without constraints.
引用
收藏
页数:12
相关论文
共 21 条
[1]  
[Anonymous], CAMPTOSAR IR INJ
[2]  
[Anonymous], 2003, Ann ICRP, V32, P3
[3]  
Aoki Y., 2011, CLUSTER NEWTON METHO
[4]   Individual Fluorouracil Dose Adjustment in FOLFOX Based on Pharmacokinetic Follow-Up Compared With Conventional Body-Area-Surface Dosing: A Phase II, Proof-of-Concept Study [J].
Capitain, Olivier ;
Asevoaia, Andreaa ;
Boisdron-Celle, Michele ;
Poirier, Anne-Lise ;
Morel, Alain ;
Gamelin, Erick .
CLINICAL COLORECTAL CANCER, 2012, 11 (04) :263-267
[5]  
Edginton AN, 2008, EXPERT OPIN DRUG MET, V4, P1143, DOI [10.1517/17425255.4.9.1143, 10.1517/17425255.4.9.1143 ]
[6]  
European Medicines Agency, 2013, GUID INV DRUG INT
[7]  
FDA, 2012, DRAFT GUID
[8]   Increased Plasma Concentrations of Unbound SN-38, the Active Metabolite of Irinotecan, in Cancer Patients with Severe Renal Failure [J].
Fujita, Ken-ichi ;
Masuo, Yusuke ;
Okumura, Hidenori ;
Watanabe, Yusuke ;
Suzuki, Hiromichi ;
Sunakawa, Yu ;
Shimada, Ken ;
Kawara, Kaori ;
Akiyama, Yuko ;
Kitamura, Masanori ;
Kunishima, Munetaka ;
Sasaki, Yasutsuna ;
Kato, Yukio .
PHARMACEUTICAL RESEARCH, 2016, 33 (02) :269-282
[9]   Clinical development success rates for investigational drugs [J].
Hay, Michael ;
Thomas, David W. ;
Craighead, John L. ;
Economides, Celia ;
Rosenthal, Jesse .
NATURE BIOTECHNOLOGY, 2014, 32 (01) :40-51
[10]   Comprehensive Pharmacogenetic Analysis of Irinotecan Neutropenia and Pharmacokinetics [J].
Innocenti, Federico ;
Kroetz, Deanna L. ;
Schuetz, Erin ;
Dolan, M. Eileen ;
Ramirez, Jacqueline ;
Relling, Mary ;
Chen, Peixian ;
Das, Soma ;
Rosner, Gary L. ;
Ratain, Mark J. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (16) :2604-2614